Gilead’s twice-yearly shot cut HIV infections by 96% in trial CNBC The data sets the stage for likely approval of Gilead's Lenacapavir for HIV prevention. Gilead (GILD) 6 days
Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention Investor's Business Daily 6 days
Undercovered Dozen: EPR Properties, Gilead, Portland General Electric, CNH Industrial + Seeking Alpha 2 weeks
Gilead Sciences, Inc. (GILD) Wells Fargo 2024 Healthcare Conference (Transcript) Seeking Alpha 2 weeks
Gilead Sciences, Inc. (GILD) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript) Seeking Alpha 2 weeks
Why This Rival To Gilead, Novartis Just Jumped 10% — And Why There Are Caveats Investor's Business Daily 3 weeks
Gilead Sciences alleges dangerous drug-counterfeiting operation at two NYC pharmacies in lawsuit CNBC 1 month
Gilead Stock Dips As ‘Non-Core’ Products Drive Its Second-Quarter Beat Investor's Business Daily 1 month
Gilead Shot Provides Total Protection From HIV in Trial of Young African Women The New York Times 3 months
Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective Investor's Business Daily 3 months
Stocks making the biggest moves midday: Gilead Sciences, Accenture, Trump Media, AMD and more CNBC 3 months
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender Investor's Business Daily 3 months
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar Investor's Business Daily 3 months
Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Seeking Alpha 3 months